|
REPORT COPYRIGHT VIOLATION IN REPLY
|
|
Message Subject
|
AstraZeneca, Oxford Jenner Institute, vaccine, AZD1222 (ChAdOx1 nCoV-19), CEPI, BARDA, GAVI
|
|
Poster Handle
|
Anonymous Coward |
|
Post Content
|
(May 22, 2019) AstraZeneca joins with BenevolentAI for drug discovery
Strategic partnership between AstraZeneca and BenevolentAI to use artificial intelligence and machine learning to identify new kidney and lung drugs.
Pharma giant AstraZeneca has announced a new long-term collaboration with artificial intelligence experts BenevolentAI.
The collaboration aims to combine AstraZeneca’s world-leading clinical data with BenevolentAI’s machine learning capabilities
and artificial intelligence to discover new drugs for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
As a recent study in Respiration shows, CKD and IPF are two of the most fatal and prevalent age-associated diseases.
[link to www.longevity.technology (secure)]
(June 5, 2020) 2 billion doses of the Oxford coronavirus vaccine will be available after a new deal that included $750m from Bill Gates, AstraZeneca says
The global supply of a potential coronavirus vaccine being developed at Oxford University has been doubled to 2 billion
after a deal including $750 million from the Bill and Melinda Gates Foundation.
The vaccine is being produced by AstraZeneca British drug maker, drawing on work by researchers from Oxford University.
It announced Thursday that it had signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi
the Vaccine Alliance to boost its supplies. The company has committed to mass-producing the vaccine before it has been proved effective, an unusual
step designed to compress the long timeline of vaccine production.
CEPI and Gavi are both charities supported the Bill and Melinda Gates Foundation and the World Health Organization.
The $750 million agreement with CEPI and Gavi will support manufacturing, procurement and distribution for 300 million of the 2 billion doses.
The statement also said that AstraZeneca struck a licensing partnership with the Serum Institute of India (SII),
the world's largest manufacturer of vaccines by volume, for 1 billion doses of the vaccine earmarked for low- and middle-income countries.
[link to www.businessinsider.com (secure)]
(June 15, 2020) AstraZeneca taps Catalent for COVID-19 vaccine finishing, packaging at Italian plant
British drugmaker AstraZeneca is shooting for the moon with its plan to produce 2 billion doses per year of a potential COVID-19 vaccine.
To reach that lofty goal, AstraZeneca has reached a deal with New Jersey-based Catalent
to help with the final stages of the shot's manufacturing.
Catalent will be tasked with finishing and packaging duties for AstraZeneca and the University of Oxford's COVID-19 vaccine candidate, AZD1222,
at its 305,000-square-foot manufacturing facility in Anagni, Italy, the CDMO said Monday.
As part of their agreement, Catalent will help AstraZeneca produce "hundreds of millions of doses" beginning in August 2020
and potentially running through March 2022, if the vaccine receives full regulatory approval.
Last week, AstraZeneca and Emergent BioSolutions inked an $87 million deal to manufacture doses of Oxford's adenovirus-based COVID-19 shot for U.S. supply.
The accord was part of the Trump administration's Operation Warp Speed initiative
to develop and rapidly scale production of targeted vaccines before the end of 2020.
For its part, Catalent will also work with Johnson & Johnson to help produce its COVID-19 vaccine hopeful.
[link to www.fiercepharma.com (secure)]
(June 29, 2020) AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID-19 shot
AstraZeneca and the government of Brazil have inked a deal valued at $127 million
to produce doses of the University of Oxford's adenovirus-based COVID-19 vaccine candidate, AZD1222,
as the country combats a rising count of new infections.
Brazil—which trails only the U.S. in terms of total reported COVID-19 cases and deaths—will make available around 30 million finished doses
of the vaccine, with roughly half that amount available by December, AstraZeneca said. Brazil has also committed to produce an additional 70 million doses,
with AstraZeneca supplying the unfinished vaccine at no cost.
The vaccine doses will be finished in Brazil by the Oswaldo Cruz Foundation, also known as Fiocruz,
as AstraZeneca does not have a vaccine production suite at its Brazilian manufacturing facility, the drugmaker said.
On Friday, local Japanese drugmaker Daiichi Sankyo said it was piecing together a supply deal with AstraZeneca for Oxford's shot
after the Japanese government agreed to sit down at the negotiating table to discuss a possible deal.
Daiichi Sankyo Biotech, a subsidiary of the Japanese drugmaker, plans to receive Oxford's undiluted vaccine, which it will finish at its own facilities.
[link to www.fiercepharma.com (secure)]
|
|
|
Please verify you're human:
|
|
|
Reason for copyright violation:
|
